state of play, page-7

We were all happy as larry during the pandemic, with GSK investing in increased capacity and Witty saying that was the new paradigm or higher heads n shoulders for Relenza.... but we all knew how that turned out.

Market was seriously unimpressed and rightly so with revenue returning to the crap mean level.

No comfort for very long term holders but to happily hold BTA, you need to wipe the slate clean, and treat 2011 as the starting point for a 5-7 year investment to give their new products, like LANI/BTA-798, and their new strategy of taking products to Phase III and beyond a real good go.